Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis.
| Publicado en: | Journal of Clinical Oncology Vol. 44; pp. 283 - 310 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Descripción no disponible. |